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Abstract 
 
All European countries face increasing challenges in the provision of equitable and comprehensive 
healthcare for their citizens in view of a number of factors including changing demographics and the launch 
of new premium priced medicines. The challenges are even more difficult among Central and Eastern 
European healthcare systems. Consequently, there is a need for countries to learn from each other to help 
address some of these challenges and to maintain sustainable systems. This was the basis of the 2-day 
conference, The Fifth International Conference: Challenges for Efficient Healthcare in Central and Eastern 
Europe, 9-10 October 2015, Belgrade, Serbia. 
 
Introduction 
 
Central and Eastern European healthcare systems face difficult challenges that need addressing. The main 
objective of this conference was to discuss these challenges and provide potential ways forward. 
 
Challenges  
 
Wija Oortwijn discussed the use of health technology assessment (HTA) for reimbursement decisions. A key 
challenge is to achieve and maintain the quality of healthcare including new innovative technologies within 
constrained budgets, which requires optimal distribution of limited resources. The results of a study 
conducted in Serbia, Slovakia, Taiwan and Brazil showed that HTA must be adapted to the needs and 
demands of individual health systems to maximize their usefulness in decision making [1]. This is still at an 
early stage in a number of these countries, with HTA processes seen as reasonably new and not always 
robust and transparent. In addition, funds for the implementation of HTA are often limited and in a number of 
countries there is also limited local information. As a result, a number of countries are forced to use 
information (reports), as well as HTA methods / procedures from other countries. The exception was Brazil 
with well-developed national and regional systems versus Serbia where HTA is currently less developed. The 
main challenges for HTA include political instability and lack of "will", resistance to the HTA process as well 
as a lack of transparency.  
 
Krzysztof Landa (President, MedInvest Scanner Ltd M.I.S., Poland) discussed HTA as a useful tool for 
investors and presented the MedInvest Scanner Database (www.medinvestscanner.com). HTA can 
significantly improve the choice process of health technologies that are most promising, and these, together 
with other methodologies, can be an important tool in order to reduce investment risk. MedInvest Scanner 
offers investors access to a database discussing potential new non-drug medical technologies for possible 
investment. Potential innovations are ranked according to HTA and EBM criteria to inform about their 
investment attractiveness. 
 
Exemplars 
 
Angela Yu from the London School of Economics discussed experiences with Managed Entry Agreements in 
China as a basis for recommendations for Central and Eastern Europe. More than 95% of the population of 
China is covered by one of the three state health-insurance schemes. In 2012, the total contributions for all 
three schemes amounted to US$115 billion. The urban scheme receives 67% of these funds; however, this 
covers only 40% of the total population. Yu explained that to date, Managed Entry Agreements have been 
established in 25 locations (20 individual provinces out of 31 and 5 municipalities). A total of 41 different 
brands and 37 different molecules have so far been covered by such agreements across China. The 
situation is being closely monitored to provide future direction.  
 
Tanja Novakovic discussed the role of patient registries in improving healthcare quality and resource 
allocation, as they are seen as a valuable source of information given concerns with patient selection in 
Phase III randomized controlled trials [2]. Several patient registries are available in Serbia including registries 
for melanoma, inflammatory bowel disease and rheumatoid arthritis; however, collecting and utilizing these 
data requires close cooperation among all key stakeholder groups including the Health Insurance Fund. 
These issues were explored further by Mark Parker when discussing real-world evidence, as routine clinical 
practice can be considerably more complicated than Phase III randomized controlled trials when taking into 
account issues such as co-morbidities. Modern technology has greatly reduced the cost of gathering clinical 
evidence. While such data are often routinely collected in some European countries [3], this does not apply 
to all European countries including Serbia. It is important to rectify this to help optimize the future use of 
resources. 
 
David Danko (Managing Director at Ideas & Solutions, Hungary) pointed out that in Serbia there is currently 
no formal review of HTA submissions as part of pricing and reimbursement negotiations and limited patient 
level data. There are potentially two frameworks for assessing the value of new technologies in Serbia; firstly, 
the value of new medicines for patients and society as a whole and secondly, their financial impact. The first 
framework takes into account the added clinical benefit of the new technology, its alignment with national 
health policy as well as social and ethical consideration, whilst the second includes a budget impact analysis 
[4].  
 
Special diseases and pharmaceuticals 
 
There is growing use of biosimilars across Europe in view of potential savings; however, uptake has been 
hampered by limited discounts to date, typically 15% to 30% [5], as well as disinformation. The latter has 
resulted in strategies to address this from the European Commission [6]. The situation is changing with Orion 
offering the Norwegian Drug Procurement Cooperation a 69% discount for biosimilar infliximab compared 
with the originator tender price (REMICADE) and 72% compared with its list price [7]. Concerns with 
potential side-effects are being countered by the Ministry of Health in Norway funding NOR-SWITCH to 
compare the effectiveness and side-effects of originators and biosimilars [7].  
 
Current prices of orphan medicinal products (OMPs) are also a growing concern given the numbers in 
development and the increasing number of new targeted cancer medicines seeking orphan status [8, 9]. 
Prices for OMPs are generally between US$10,000±30,000 per patient, per month or more, with limited 
reimbursement hurdles, although this is changing [10,11]. High prices have been justified by an estimated 
US$2.6billion to develop a new medicine; however this figure is criticized [12,13]. Concerns with the 
attractiveness of the OMP market was also debated; tempered by Sanofi paying over US$20billion for 
Genzyme [14]. Concerns with the high prices and limited health gain with most new cancer medicines is also 
resulting in requests for greater price transparency [12,13,15,16]. 
 
Bojan Trkulja (INOVIA; Association of Innovative Drug Manufacturers, Serbia) discussed concerns that 
Serbia has the lowest access to innovative therapies in comparison with other countries in the region. From 
2007± 2010, 228 new medicines were registered in the EU. From these, 133 were reimbursed in Italy, 148 in 
Slovenia, 62 in Croatia, 83 in Bulgaria 83 yet only 12 in Serbia. From 2010, 139 new medicines were 
registered in EU, of these; Bulgaria reimbursed 44, Croatia 27 and Serbia only 1. The appropriate use of new 
and existing medicines can reduce disease burden. This requires improved communication between key 
stakeholder groups, as well as greater transparency and fairness in decision making. It also requires 
pharmaceutical companies to accept only a minority of new medicines are truly innovative [16].  
 
Neven Lovrin (Consultancy Terminal, d.o.o., Croatia) reviewed the cost-effectiveness of 
ombitasvir/paritaprevir/ritonavir +/- dasabuvir from a Croatian perspective in patients with chronic hepatitis C 
(HCV). New HCV therapies are highly cost-efficient including patients with HCV genotype 1 previously 
treated with other regimes; however, given the prevalence of HCV and high requested prices there are 
concerns with their budget impact, leading to considerable discounted prices for reimbursement across 
countries [17-19].  
 
Timothy Johnston (The World Bank Group, Austria) discussed the challenges and priorities of 
pharmaceutical policy in middle-income countries. Availability, purchasing, i.e. how to get the best price for 
quality generics and new medicines, financing - including preventing catastrophic out of pocket payments, 
and the rational use of medicines are the main challenges facing middle-income countries. This increasingly 
includes non-communicable diseases. Algorithms for assessing the clinical and economic benefits of new 
medicines is one way forward, including collecting publicly available data as well as decisions from other 
countries.. Other issues regarding reimbursement negotiations include identified health priorities, applicability 
of the data from other countries, available funds for medicines, and healthcare delivery capacity.  Optimizing 
³YDOXHIRUPRQH\´UHTXLUHVGLIIHUHQWVWUDWegies for new versus generic medicines. Available data can be used 
to monitor rational use, track budgets, identify patterns of abuse/ overuse as well as enforcement of any 
price-volume agreements.  
 
Alan Haycox dLVFXVVHGWKHLPSRUWDQFHRIWKHµSDWLHQWYRLFH¶DQGRWKHUFRQWULEXWRU\VWDNHKROGHUVLQvolved in 
the HTA process. NICE actively seeks the widest possible input from clinical experts, patient interest groups 
and society, with the NICE technical team subsequently summarizing all responses for Committee members 
prior to producing the Final Appraisal Determination to be discussed at the Appraisal Committee [20]. Such 
an extensive consultation adds considerable time to the review process; however, it also provides the widest 
possible opportunity for all interested parties to contribute to decision making. NICE ensures every Appraisal 
committee meeting has clinicians and patient representatives with direct experience of the disease in 
question, with patientV¶YRLFHVVHHQDVcrucial. However, it is recognized patients may be focused on a 
particular disease restricting their focus. Consequently, there is a need for HTA groups to address this and 
reflect the values of society as a whole given the opportunity costs involved. This includes emotive areas 
including new cancer medicines and OMPs often with limited health gains [21].  
 
There are concerns with HTA submissions and their evaluation within Central and Eastern European 
Countries in terms of a lack of local skills. Consequently, attendees on the second day of this meeting had an 
opportunity to address this by taking part in a competitive healthcare ³Zar game´ through simulating a patient 
population with chronic HCV in Serbia treated with new medicines in order to help eradicate the disease 
combined with central tendering approaches. 
 
Conclusion 
 
There are appreciable differences between countries in terms of access and reimbursement to new 
medicines and their assessment. HTA is a way forward to enhance transparency in decision making and 
access. Patient-level data can also improve decision making. These developments are needed in Serbia to 
enhance access to new valued innovative medicines as well as ensure patients with non-communicable 
diseases are well treated within available resources. This will require cooperation between all relevant 
stakeholder groups.  
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